Market research
ANAB AnaptysBio Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 87.0909
- Dividend yield
- Not available
- Beta
- 0.4
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US0327241065
- Market cap
- 2B
- P/E ratio
- Not available
- Analyst target
- 87.0909
- Dividend yield
- Not available
- Beta
- 0.4
About
About AnaptysBio Inc
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company's products include Rosnilimab, a selective pathogenic T cell deplete which completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis; ANB033, a CD122 antagonist, which is in a Phase 1b trial for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody which is in Phase 1a trial that specifically targets plasmacytoid dendritic cells and inhibits interferon secretion and modulates antigen presentation; dostarlimab, a PD-1 antagonist for various solid tumor indications; and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. It focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has collaborations agreement with GSK and Vanda. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ANAB discussion.
5 years, 4 months ago
AnaptysBio, Inc is currently in a long term uptrend where the price is trading 5.7% above its 200 day moving average.
From a valuation standpoint, the stock is 99.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.3.
AnaptysBio, Inc's total revenue rose by 1900.0% to $60M since the same quarter in the previous year.
Its net income has increased by 266.0% to $34M since the same quarter in the previous year.
Finally, its free cash flow grew by 334.3% to $37M since the same quarter in the previous year.
Based on the above factors, AnaptysBio, Inc gets an overall score of 5/5.